ASH 2023 | Challenges with managing the high rates of infections seen in patients with AML
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges of approaching the high risk of infections seen in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Dr Žučenka highlights factors influencing infection risk in these patients, commenting on the importance of antifungal, antibacterial, and antiviral prophylaxis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, Astellas, Pfizer, Novartis, Janssen
Honoraria: Abbvie, Astellas, Novartis, Janssen
Travel Expenses: Abbvie, Novartis, Janssen, Takeda
